Chagas' disease, caused by the intracellular protozoan parasite Trypanosoma cruzi, is a major cause of heart failure in endemic areas. Antigenic mimicry by T. cruzi antigens sharing epitopes with host macromolecules has been implicated in the pathogenesis which is thought to have a significant autoimmune component. We report herein on the cloning and characterization of a full-length cDNA from a T. cruzi expression library encoding a protein, TcP0, that is homologous to the human 38-kD ribosomal phosphoprotein HuP0. The T. cruzi PO protein shows a clustering of residues that are evolutionarily conserved in higher eukaryotes. This includes an alanine-and glycine-rich region adjacent to a highly charged COOH terminus. This "hallmark" domain is the basis of the crossreactivity of the highly immunogenic eukaryotic P protein family. We found that T cruzi-infected individuals have antibodies reacting with host (self) P proteins, as well as with recombinant TcP0. Deletion of the six carboxy-terminal amino acids abolished the reactivity of the T. cruzi infection sera with TcP0. This is similar to the specificity of anti-P autoantibodies described for a subset of patients with systemic lupus erythematosus (SLE) (Elkon, K., E. Bonfa, K. Llovet, W. Danho, H. Weissbach, and N. Brot. 1988. Proc. Natl. Acad. Sci. USA. 85:5186). These results suggest that T. cruzi P proteins may contribute to the development of autoreactive antibodies in Chagas' disease, and that the underlying mechanisms of anti-P autoantibody may be similar in Chagas' and SLE patients. This study represents the first definitive report of the cloning of a full-length T. cruzi antigen that mimics a characterized host homologue in structure, function, and shared antigenicity.
T he protozoan hemoflagellate, Trypanosoma cruzi, is the causative agent of Chagas' disease, which is endemic in many Latin American countries. During the chronic stage of infection, an abundant inflammatory infiltrate is found in myocardial and nervous tissues (1, 2) . This, coupled with the rare detection of parasites in damaged tissues, has led to the hypothesis that autoimmune mechanisms may contribute to tissue injury in Chagas' disease.
Chagas' disease provides an excellent model for exploring the mechanisms of autoimmunity, because the etiology of the disease is known. Regarding humoral response, relatively few antibodies against different self-antigens have been characterized in T. cruzi-infected individuals (3) (4) (5) (6) . To date there have been only two reports on the molecular cloning of T. cruzi antigens, one complete (7) and the other a 35-residue peptide (8) , containing antigenic epitopes which may induce antibodies that crossreact with self proteins. In general, most of the T. cruzi antigens that have been reported are partial sequences comprised mainly of repetitive epitopes (9, 10) . Of the identified nonrepeat antigens, complete sequence information is available for only a few (7, 9, 11) .
Herein, we report the cloning, expression, and biochemical characterization of a fuU-length cDNA encoding a 35-kD T cruzi antigen, TcP0, that is constitutively expressed and associated with the ribosomal translation machinery. TcP0 is highly homologous to the human 38-kD type ribosomal P protein HuP0, and is conserved in other Trytmnosoma species. We show that T. cruzi-infected individuals have antibodies against TcP0 which, in most cases, crossreact with the homologous human ribosomal P proteins. Of particular interest to our study are previous reports which demonstrated that a subset of patients with SLE have autoantibodies against ribosomal P proteins (12, 13) .
The uniformity in the target epitope of the autoantibodies against the ribosomal P proteins of humans and mice with SLE (14) , of a mouse mAb derived from immunization with heterologous (chick) ribosomes (15) , and of TcP0 in T. cruziinfected individuals, is suggestive of similar mechanisms that lead to the generation of anti-P autoantibodies either spontaneously (human and mouse SLE) or after infection. We propose that exposure to T. cruzi P proteins may result in the generation of autoreactive antibodies which could contribute to the autoimmune pathogenesis characteristic of Chagas' disease.
linker sequence using appropriate enzymes for in-frame fusion with the amino terminus of B-galactosidase. COOH-terminal deletions were initiated from the 3' end (XhoI) of the TcP0 phagemid insert and treatment with exonuclease III. Recombinant antigens were purified from 500 ml of IPTG-induced cultures (10) . The inclusion bodies were sequentially solubilized in two washes each of 10 ml TNE (50 mM Tris, pH 8.0, 100 mM NaC1, and 10 mM EDTA) containing 2, 4, and 8 M urea. Fractions containing the recombinant antigen (usually the 4 and 8 M urea supernatants) were pooled, dialyzed against PBS, and concentrated by precipitation with 30% ammonium sulfate. Purification to homogeneity was accomplished by preparative SDS-PAGE electrophoresis, followed by excision and electroelution of the recombinant antigens as described (25) .
Productwn of Rabbit Antiserum against Recomtn'nant 7~PO. An adult rabbit (New Zealand White; R & R Rabbitry, Stanwood, WA) was immunized with purified rTcP0 as described (26) , except that rlbl-3 was excluded.
Antigens. Parasite and cell lysates were prepared by freeze/thaw lysis of pellets in SDS sample buffer, but without glycerol and B-ME. Insoluble material was separated from the supernatant by centrifugation at 10,000 rpm in a microfuge. 77, cruzi ribosomes were isolated as previously described for mammalian cells (13) , and the final pellet resuspended in SDS sample buffer. Protein concentrations were determined using the BCA protein assay kit (Pierce Chemical Co., Rockford, IL).
In vitro Translation and Immunolorecipitation. 10/zg of total stagespecific T. cruzi RNA was translated in rabbit reticulocyte lysate in the presence of [3SS]methionine, as suggested by the supplier's protocol (Promega Corp., Madison, WI). Typically, 100,000 cpm of the total translated mixture was diluted to 250/~1 with solubilization buffer (20 mM Tris, pH 8.0, 50 mM NaC1, 1% Triton X-100, 0.5% deoxycholic acid, 50 /~g/ml gentamycin, 5 mM EDTA, 0.1 mM PMSF, and 0.1 mM iodoacetic acid). 2/~1 of anti-TcP0 antiserum was added and incubated on ice for 2 h. Complexes were precipitated by the addition of 40/xl of a 10% vol/vol fixed Staphylococcus aureus (Cowan I) and further incubation for I h. After centrifugation through a 1-M sucrose cushion, immunoprecipitates were washed twice each in solubilization buffer and mixed detergent buffers (0.05% NP-40, 0.1% SDS, 0.3 M NaC1, and 10 mM Tris, pH 7.6), and resuspended in 50 #1 SDS sample buffer. 10-/xl samples were resolved on SDS polyacrylamide gels and prepared for fluorography by treatment with Entensify TM (Du Pont Co., Wilmington, DE), as specified by the manufacturer.
Patient Sera. T. cruzi infection sera were from well characterized patients (confirmed by both parasitological and serological evaluation) from Brazil (10). Anti-P positive SLE sera were from North American patients and have been described elsewhere (27, 13) . Sera from uninfected individuals were from Seattle and nonendemic areas of Brazil.
Immunoblot Analysis. 5-10 #g of parasite or cell extracts or 0.5-1.0/xg of recombinant antigens were separated on 12.5% SDS-PAGE (28) , and transferred electrophoretically to nitrocellulose membranes (29) . Reactivities of the antisera were assessed as previously described (25) using [12sI]Protein A, followed by autoradiography.
ELISA. Microtitre plates (Probindr~; Falcon Plastics, Cockeysville, MD) were coated overnight with synthetic peptide corresponding to the COOH-terminal 22 amino acids of the human ribosomal P2 protein conjugated with thyroglobulin (27) at a concentration of 250 ng per well in 50/zl of coating buffer (15 mM NazHCO3, 28 mM NaHCO3, pH 9.6). Control wells were coated with free thyroglobulin. After washing with PBS/0.1% Tween-20, 50/zl of sera (1:200 dilution) were added and incubated for 30 min at room temperature. Bound antibody was detected using Protein A-horseradish peroxidase (Zymed Laboratories, Inc., Seattle, WA) as described (30 Ai GCCGTCCGTCTCCGAGGCCAAGCGGGAGTACGAGGAGCGTTTCAATGGCTGCCTCACC~GTACGGCCGCGTGCTTTTCTGcCT~TGGATAACGTCC 100
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6TGCTGGCATCCCGACGGCGGCGACCTTGCCACATATGATCATGGACGCGTTCAAGACCCTTcTTGGCGCCTCCGTTGCCACCGAATACGAGTTCGATGA 800 ment. An open reading frame of 966 nucleotide encoding a predicted protein of'~35 kD is followed by a 73 nucleotide 3' untranslated portion terminating in a stretch of poly(A) residues. Southern analysis of T. cruzi genomic DNA digested with enzymes that cut both within and outside of TcP0 revealed multiple hybridizing bands when probed with either the fulllength TcP0 insert (Fig. 2 A) or a 3' probe (AN222; Fig.  1 A) . These results indicate that at least two copies of TcP0 are present within the genome. This has also been confirmed from the nucleotide sequences of one other partial TcP0 cDNA. The results revealed that although both cDNA clones have identical TcP0 nucleotide sequences within their coding segments, they differ in the sequences and lengths of their 3' untranslated regions (Fig. 1 B) . The weaker hybridizing bands in the EcoRV and PstI lanes of Fig. 2 may reflect on the lengths of the complementary sequence overlap with the uniformly labeled probes or the presence of more divergent members of the TcP0 family. Fig. 2 (32) , revealed significant homology with members of the family of acidic phosphorylated ribosomal proteins known as the "P" or "A" proteins (12, 13, 33) . Fig. 3 A shows alignment of the deduced primary structure of T. cruzi P0 with those of human (HuP0, 33) and yeast (YP0, 34). TcP0 has an overall homology of 58% (36% identity, 22% conservative substitution) with HuP0 and 62% (38% identity, 24% conservative substitution) with YP0. The lengths (322, 317, and 312 amino acids), molecular masses (35, 35.3 , and 33.8 kD), and isoelectric points (5.1, 5.8, and 4.6) of TcP0, HuP0, and YP0, respectively, are very similar.
The T. cruzi PO shows a clustering of residues that are evolutionarily conserved in higher eukaryotes. This includes an alanine-and glycine-rich region adjacent to a highly charged COOH terminus. This domain is the "hallmark" of the eukaryotic P protein family, and is the basis of their immunological crossreactivity (15, 27, 35) . Like other P0 proteins, TcP0 has a arginine-and lysine-rich region (located at an equivalent position; residues 42-71). This region is hypothesized to be involved in the binding to rRNA (36) . The COOH terminus of the P proteins (P0, Pl, and P2) can be divided into two portions: a variable but highly charged region, and the highly conserved hydrophobic COOH terminus ( (Fig. 3 B) . the transcription pattern, we performed Western analysis of T cruzi lysates using a rabbit antiserum raised against rTcP0. As shown in Fig. 4 B, the antiserum detected a single protein of "~38 kD in both the insect (epimastigote) and mammalian (trypomastigote and amastigote) stages. Thus the expression of TcP0 reflects the transcript abundance. The serum did not crossreact with proteins of sizes expected for the T. cruzi equivalent of Pl and P2. The same blot also shows that purified T. cruzi ribosomes (lane r/b) contain TcP0. The postribosomal supernatant, when subjected to similar analysis, also showed an immunoreactive band at 38 kD (not shown). This is in agreement with studies from other species demonstrating the presence of P proteins in ribosomefree cytoplasm (35, 41, 42) . Fig. 4 B also shows that rabbit anti-rTcP0 antisera crossreacted with a 38-kD species in both the bloodforms and procyclic forms of T. brucei. To determine whether endogenous TcP0 is subjected to any posttranslational modification that significantly alters its mobility, immunoprecipitates of TcP0 from in vitro translations using total T. cruzi KNA (Fig. 4 B; lanes IVT/IP) and in vitro transcribed TcP0 cDNA as template (not shown) were performed. The sizes of the precipitated bands were indistinguishable from those revealed in immunoblots of cell lysates. Taken together, these results suggest that, posttranslational events do not significantly affect the size of TcP0, and that the cloned cDNA encodes authentic TcP0 protein. Although the predicted molecular mass of TcP0 is "~35 kD, the endogenous as well as in vitro translated products migrated more slowly ('~38 kD). This is attributed to the peculiar secondary structure of the P proteins (33) .
Reactivity of Chagas' Patients with T. cruzi and Human P Proteins. To address the question of whether individuals with T. cruzi infection produce antibodies against TcP0, sera from 10 patients were tested on immunoblots (Fig. 5 A) containing purified rTcP0 (lanes A), as well as total trypomastigote lysate (lanes B). All ten patients (1-10) showed binding to rTcP0. The smear of bands towards the upper portion of the gel (lanes A) is the result of aggregation of rTcP0 after purification. The specificity of the reactivity of patient sera on rTcP0 is demonstrated below (Fig. 6) . Thus, T. cruzi-infected individuals produce anti-TcP0 antibodies. Pooled sera from uninfected individuals showed no reactivity. To determine whether Chagas' patients produce antibodies reactive to human P proteins, we tested the same 10-patient sera described above by ELISA using an available synthetic Peptide corresponding to the COOH-terminal 22 amino acid residues (C-22) of the human P2 protein (35) . In human P proteins, the C-22 terminal residues are identical for P0, P1, and P2, with the exception of a single conservative substitution in P0 (an aspartic to glumatic acid) at position nine with respect to the COOH terminus (Fig. 3 B) . This substitution was shown to have no effect on the binding competence of patient sera (13) . Fig.  5 B shows that 9 of 10 sera reacted with the human Peptide with absorbance values ranging from 3.1 to 24-fold higher than the mean of sera from uninfected controls. These findings indicate that most Chagas' patient sera with anti-T, cruzi P protein antibodies crossreact with self P proteins.
Epitope Mapping of Anti-TcPO Antibody. To determine the TcP0 epitope(s) recognized by T. cruzi-infected individuals, we tested the reactivities of patient sera on truncated versions of rTcP0. Fig. 1 indicates the end points of the dones used, all of which were expressed in Escherichia coil as fusion proteins with 3-galactosidase. TcPOAN222 lacks the amino 222 residues and contains only the 100 COOH-terminal portion amino acids of TcP0. When expressed in E. coil, this COOH-terminal fusion protein maintained reactivity with a pool of Chagas' sera (Fig. 6 A) . The weaker and lower bands are probably the result of partial degradation of the fusion protein. Therefore, major antigenic determinant(s) of TcP0 recognized by Chagas' sera reside within the COOH terminal of the molecule. To map the epitope(s), we performed 3' deletions resulting in clones with COOH-terminal truncations of 6 (TcPOAC6), 33 (TcPOAC33), and 43 (TcPOAC43). All three clones maintained the same fusion amino add residues as TcP0 until their respective deletion junctions. Coincidentally, their reading frames continued past the P0 sequence in to the plasmid for an additional 59 amino acid (-,~9 kD). Immunoblotting of TcPOAC33 and TcPOAC43 with a pool T. cruzi infection sera of Chagas' patient sera showed no reactivity on the deleted recombinants (not shown). It is interesting that when TcPOAC6 was immunoblotted with Chagas' sera from ten different patients (those shown in Fig. 5 ), their reactivities were abolished despite the fact that they all reacted with the wild type TcP0 (Fig. 6 A) . Fig. 6 B is a control with rabbit anti-rTcP0 sera.
SLE Patients Contain Antibodies that Crossreact with TcPO. Approximately 10-20% of patients with SLE possess antiribosomal antibodies. These antibodies react predominantly with three of the ,o80 ribosomal proteins: P0, P1, and P2 (12, 13) . Sera from these patients also react with the homologous antigens present in rats, shrimp, and yeast (12) . We therefore tested the binding of eight SLE sera previously characterized as anti-human P positive (27, 14) on TcP0. We found that although all eight SLE sera reacted with rTcP0 with varying intensities, they either showed no reactivity or bound weakly to truncated rTcPOAC6. Fig. 7 (A and B) is representative of two individual SLE sera, showing their variable reactivities with rTcP0 (lanes 1) and rTcP0AC6 (lanes 2). The sera also reacted with a 38-kD band in T. cruzi lysate (lanes 4) with intensities proportional to their respective reactivities on rTcP0. Fig. 7 A, lane 5 is a control showing that the band detected by the rabbit anti-TcP0 sera on T. cruzi lysate comigrates with the 38-kD band detected by SLE sera. As expected, the SLE sera reacted with proteins with migrations characteristic of the P protein family in human K562 cell ly- sates (lanes 3). The SLE sera containing anti-human P activity also reacted with other species in T. cruzi lysates, including a very strong ~15-kD band and two weaker bands in the ~17-kD range. Any of these might correspond to the T. cruzi equivalent of P1 and P2.
Discussion
We report on the cloning and characterization of a T. cruzi full-length cDNA, TcP0, identified as the parasite equivalent of the ribosomal phosphoprotein P0. The evidence supporting the identity of the cDNA as TcP0 is the homology (~60%) to other eukaryotic P0 proteins in sequence, size ('~38 kD), acidic isoelectric point, and ribosomal localization. TcPO is present as multiple copies within the genome, and for at least two sequenced cDNAs, they have identical coding segments, but diverge markedly in their 3' untranslated regions. TcP0 is transcribed as a "~l.3-kb mRNA that is constitutively expressed in all stages of the parasite life cycle. Cross-species studies demonstrated that P0 is highly conserved in other Trypanosoma species at both the nucleotide and protein levels, as demonstrated by Southern and immunoblot assays.
The 38-kD TcP0 protein, like the mKNA, is constitutively expressed and is associated with the ribosomal translation machinery. This constitutive expression coupled with the crossspedes conservation strongly suggests that TcP0 serves a housekeeping function, as expected for a P0 ribosomal protein.
Immunoblot analysis with ten randomly selected sera from T. cruzi-infected individuals, revealed that all contained IgG antibodies against TcP0, albeit of varying levels.
In higher eukaryotes, the P protein family comprises three antigenically crossreactive proteins P0, P1, and P2 (12, 13, 15, 33) . P0, the largest protein of the family, has an apparent molecular mass of '~38 kD, while Pl and P2 migrate as a doublet in the 14-19 kD on SDS-polyacrylamide gels. These proteins all possess an alanine~ and glycin~rich region of 20-30 residues adjacent to a highly charged C O O H terminus, but show much lower homology in the remainder of the protein. Pl and P2 are believed to be functional homologues of the bacterial proteins L7/L12, and P0 is thought to be the homologue of the L10 protein. These proteins are known to play an essential role in the elongation step of protein synthesis (39, 43) . The proteins form a pentameric complex composed of two molecules each of Pl and P2, and one of P0 (33, 35, 44) . The carboxy 17 amino acid residues of the P proteins are shared both within and across species (33, 35) . In addition, a mouse mAb raised against chicken ribosomes was shown to bind to all three of the human P proteins (27, 15) .
We mapped the antigenic epitope(s) of TcP0, and demonstrated that the reactivities of sera from T. cruzi-infected individuals require a single linear determinant. Deletion of the carboxy six hydrophobic residues abrogates the immunological reactivity of TcP0 on Western blots. This is analogous with the binding properties of SLE anti-P autoantibodies where the only required epitope has been mapped to the carboxy 11 residues (27) . We demonstrated that anti P-positive SLE sera do in fact recognize TcP0. The variable degree of reactivities of the SLE sera on TcP0 is in agreement with previous studies on human P proteins which revealed that different SLE patients have variable specificities and reactivities with shorter, as well as modified peptides of the Cll residues (27) . Given that the hydrophobic COOH-terminus of TcP0 is different from those of the human P proteins, it is surprising that anti-P SLE sera reacted as well as they did on TcP0. More interesting, is the finding that, like sera from T cruzi-infected individuals, the reactivity of SLE sera on TcPOAC6 is either abrogated or greatly reduced. In addition, the SLE sera also showed reactivities on parasite lysates with proteins of sizes characteristic of P0, P1, and P2. Given that the hydrophobic terminal residues of T. cruzi P1 is identical to those of the human P proteins (see below and Fig. 3 B) , it is very likely that the strong reactive "~15-kD 'band' detected by the SLE sera on T. cruzi lysate is TcPl and/or TcP2. The SLE sera also reacted with two additional bands of '~50 kD (above P0) on parasite lysates. Whether these represent modified forms or complexes of T. cruzi P proteins, or different T. cruzi antigens that are shared with human and T. cruzi, remains to be determined. The reciprocal assay using the antigenic C22 peptide of human P2 demonstrated that most T. cruzi-infected individuals possess antibodies that crossreact with self-ribosomal P proteins. However, their reactivities did not correlate with the results of the immunoblots on rTcP0, indicating that different T. cruzi-infected individuals show variable crossreactivities for a substituted COOH-terminal domain.
The results of the Western blot and immunoprecipitations indicate that either TcP0 is not antigenetically related to T. cruzi P1 and P2, or that the specificity of the rabbit antiTcP0 serum does not include the conserved C O O H terminus. The C O O H terminus of TcP0 (which shows differences in the linear arrangement of the residues with other P proteins), may also be different from that of the T. cruzi P1 and P2. This is not unreasonable given that a cloned T. cruzi sequence encoding a 35-residue peptide named JL5 (8) has a C O O H terminus that is different from TcP0, but almost identical to that of the human P proteins (12/13 identical). JL5 does not represent a cloned fragment of TcP0 since it differs in sequence, and detects an 0.7-kb transcript too small to encode P0, but adequate to encode P1 or P2. It is different from P2 (Skeiky et al., unpublished results) and appears to represent the COOH-terminal portion of P1 (45) . This could explain the lack of immunological crossreactivity between TcP0, TcPl, and TcP2 of T. cruzi using the rabbit anti-TcP0 serum. The differences in the specificity of the human and rabbit sera may reflect outcomes of antigenic stimulation initiated by T. cruzi infection versus immunization with purified monovalent rTcP0.
Levitus et al., (46) recently demonstrated that sera from Chagas' heart disease patients crossreact with recombinant human ribosomal Pl and P2 proteins. In addition, it was previously shown (8) that immunoselected antibodies against JL5 recognize a predominant 38-kD antigen on T. cruzi lysate which, presumably, is TcP0. However, it remains unresolved whether the JL5-immunoselected reactivity was initiated through recognition of antigenic determinant(s) of TcP0 or JLS. Nevertheless, this lends further support to our argument that, despite the differences in the fine organization of the COOH-terminal residues of TcP0, antibodies directed against it can crossreact with the COOH-terminal region of the prototype P proteins both within and across species. We demonstrated that the reciprocal also holds true.
It was also shown that 57% (of 44 patients) of selected T. cruzi-infected individuals (chronic Chagas' heart disease) reacted with the C13 terminal residues of JL5 (46) . In our studies, we found that all ten randomly selected T cruzi infection sera recognized TcP0. The combined results suggest that the antibodies against T. cmzi ribosomes can have unique, as well as shared specificities for the P protein family both within, as well as across species.
The possibility that TcP0 antibodies found in sera of T cruzi-infected individuals are the result of leakage of self P proteins and subsequent immunization is unlikely since not all sera reacted with the human C22 peptide, although they all reacted with TcP0. Hines et al. (14) demonstrated that in the autoimmune MRL mice, anti-P autoantibodies could be induced by immunization with xenogenic A. salina ribosomal P proteins, but not by syngenic mouse ribosomes. In addition, it was shown that as with the spontaneous anti-P autoantibodies of MR,L mice, the induced anti-P autoantibodies were exclusively directed against the COOH-terminus. The ability ofA. salina P proteins to induce anti-P autoantibodies was attributed to a single nonconservative substitution in the COOH-terminal 11 residues (serine in mouse and glutamic acid in A. salina).
We propose that through mechanisms involving molecular mimicry, the ribosomal P proteins participate in the induction of autoreactive antibodies in Chagas' disease. This is made possible because of differences at the COOH terminus of the parasite (particularly TcP0) and host P proteins. Through synergistic mechanisms, the T. cruzi P proteins (P0, P1, and P2) could provide a multivalent epitope(s) which may be necessary for the establishment of an autoimmune process similar to that described for the murine system (14) .
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